Can I stay at 5 mg of tirzepatide as my maintenance dose?
Yes — 5 mg tirzepatide produces about 15% weight loss over 72 weeks in trials. Whether it's the right long-term dose depends on your goals and tolerability.
Updated May 19, 2026 · 4 min read
Yes — staying at 5 mg of tirzepatide is a legitimate clinical choice, not a failure to complete the protocol. In SURMOUNT-1, participants on 5 mg tirzepatide lost a mean of 15.0% of body weight at 72 weeks. That's meaningful weight loss by any standard.
The question isn't whether 5 mg works — it does. The question is whether 5 mg is the right level for your specific goals, your tolerability at higher doses, and your cost situation.
What 5 mg tirzepatide actually achieves
From SURMOUNT-1 (tirzepatide for weight management, 72 weeks):
| Dose | Mean weight loss | % achieving ≥20% loss |
|---|---|---|
| 5 mg | -15.0% | 32% |
| 10 mg | -19.5% | 51% |
| 15 mg | -20.9% | 57% |
| Placebo | -3.1% | 3% |
The jump from 5 mg to 10 mg is the largest single-step increment in the dose-response curve — about 4.5 percentage points. The jump from 10 mg to 15 mg adds roughly another 1.5 percentage points. If you're at 5 mg, you're below the steepest part of the efficacy curve and there's real additional benefit at 10 mg for most people.
For type 2 diabetes (SURPASS trials): 5 mg tirzepatide produced approximately -1.87% HbA1c reduction on average, which is clinically meaningful. Higher doses pushed this to -2.4% at 15 mg.
When 5 mg makes sense as your maintenance dose
You've met your weight goal. If 5 mg has gotten you where you wanted to be and you're maintaining that weight, there's no clinical reason to push higher. The goal is the outcome, not the dose. Many people who stop at 5 mg are doing so because it worked.
You can't tolerate higher doses. Some patients find that 7.5 mg or above produces persistent nausea, significant constipation, or heartburn that doesn't resolve after 4–6 weeks at the new step. For these patients, the dose-response improvement isn't worth the quality-of-life cost. Staying at 5 mg with reliable tolerability beats struggling at 10 mg.
Cost is a factor. Tirzepatide is sold in fixed-dose pens — a 5 mg pen costs less than a 10 mg or 15 mg pen. If you're paying out of pocket and 5 mg is producing satisfactory results, the cost efficiency of staying at 5 mg is real.
You're on Mounjaro for T2D and glucose is controlled. For diabetes management, the HbA1c reduction at 5 mg (-1.87%) may be sufficient for your individual target. If your prescriber is satisfied with your glycemic control at 5 mg, there's no mandate to push higher.
When to consider going higher
If you choose 5 mg as your maintenance and then experience one of these, the conversation about stepping up is worth having:
- Weight regain after initially losing on 5 mg. Some patients plateau or regain slightly over 6–12 months at 5 mg — this can signal that a higher dose is needed for long-term maintenance
- HbA1c climbing despite 5 mg. Diabetes is progressive, and disease advancement over time may outpace what 5 mg can manage
- You haven't reached your weight goal. If you're at 5 mg and still far from your target, stepping to 10 mg has a well-characterized benefit in the SURPASS and SURMOUNT data
The step-up decision guide covers the signals in detail — both for moving up and for staying put.
The "sweet spot" concept
Tirzepatide's titration protocol calls 5 mg a maintenance-capable dose — it's not just a transitional step. The prescribing information acknowledges that some patients will remain at 5 mg long-term, and clinical experience confirms this happens regularly.
The "you must reach 15 mg" framing that sometimes appears in patient communities misreads the data. Higher doses produce more weight loss on average across populations. For an individual patient, the right dose is the lowest one that achieves and maintains the target outcome with acceptable side effects. For some people, that's 5 mg.
Practical logistics at 5 mg maintenance
- Pen availability. 5 mg Zepbound and Mounjaro pens are widely stocked — this dose isn't unusual enough to create supply issues.
- Insurance prior authorization. Some insurers require documentation of titration to a "maximum tolerated dose." If you're staying at 5 mg because higher doses caused intolerable side effects, document that in your chart. Your prescriber can note the tolerability rationale so PA renewals don't require a justification battle.
- Monitoring. At any maintenance dose, annual HbA1c (for T2D patients) or periodic weight check-ins help confirm the dose is still doing its job. Weight regain on a stable dose is a signal, not a failure — it's information.
For more on compounded options at 5 mg, see compounded tirzepatide.